TruAlt Bioenergy earnings calls.

TruAlt Bioenergy reported 9-month total income of 1,187 croreCurrent reported value: 1,187 crore. No comparable prior figure is available in the source record., up 13.28Current reported value: 13.28. No comparable prior figure is available in the source record.% YoY, with PAT of 35.92 croreCurrent reported value: 35.92 crore. No comparable prior figure is available in the source record. growing 2.8Current reported value: 2.8. No comparable prior figure is available in the source record.% despite Q3 operational disruptions. The ethanol segment faced headwinds—Karnataka farmer protests and delayed grain-based plant commissioning limited Q3 operations to ~58 operating days, resulting in only 7.6 crore litersCurrent 7.6 crore liters. Reported change: Below potential. volume. However, all five ethanol plants are now fully operational, targeting 90-95% capacity utilization in Q4 FY26. The CBG segment demonstrated strong execution with 63%Current 63%. Reported change: +1940bps YoY. EBITDA margin and 43% PAT margin for 9M, validating the operating model ahead of the 24-plant expansion through GAIL and Sumitomo JVs. The proposed 100 million liter SAF facilityCurrent reported value: 100 million liter SAF facility. No comparable prior figure is available in the source record. in Andhra Pradesh (₹2,000 crore capex, 22-25% EBITDA target) positions the company ahead of India's emerging SAF mandate. Key risks include Q4 ramp-up execution, delayed policy clarity on ethanol pricing for private OMCs, and feedstock cost volatility impacting DDGS economics.